Anish Chakkumkal, Schumann Benjamin, Pereira Claney Lebev, Seeberger Peter H
Department for Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1, 14424 Potsdam, Germany.
Department for Biomolecular Systems, Max Planck Institute of Colloids and Interfaces, Am Mühlenberg 1, 14424 Potsdam, Germany; Institute of Chemistry and Biochemistry, Freie Universität Berlin, Arnimallee 22, 14195 Berlin, Germany.
Chem Biol. 2014 Jan 16;21(1):38-50. doi: 10.1016/j.chembiol.2014.01.002.
Carbohydrate antigens have shown promise as important targets for developing effective vaccines and pathogen detection strategies. Modifying purified microbial glycans through synthetic routes or completely synthesizing antigenic motifs are attractive options to advance carbohydrate vaccine development. However, limited knowledge on structure-property correlates hampers the discovery of immunoprotective carbohydrate epitopes. Recent advancements in tools for glycan modification, high-throughput screening of biological samples, and 3D structural analysis may facilitate antigen discovery process. This review focuses on advances that accelerate carbohydrate-based vaccine development and various technologies that are driving these efforts. Herein we provide a critical overview of approaches and resources available for rational design of better carbohydrate antigens. Structurally defined and fully synthetic oligosaccharides, designed based on molecular understanding of antigen-antibody interactions, offer a promising alternative for developing future carbohydrate vaccines.
碳水化合物抗原已显示出有望成为开发有效疫苗和病原体检测策略的重要靶点。通过合成路线修饰纯化的微生物聚糖或完全合成抗原基序是推进碳水化合物疫苗开发的有吸引力的选择。然而，对结构-性质相关性的了解有限阻碍了免疫保护性碳水化合物表位的发现。聚糖修饰工具、生物样品的高通量筛选和三维结构分析方面的最新进展可能会促进抗原发现过程。本综述重点关注加速基于碳水化合物的疫苗开发的进展以及推动这些努力的各种技术。在此，我们对可用于合理设计更好的碳水化合物抗原的方法和资源进行了批判性概述。基于对抗原-抗体相互作用的分子理解而设计的结构明确且完全合成的寡糖，为开发未来的碳水化合物疫苗提供了一个有前景的替代方案。
